Press Release: For those who invested or watched Mainz Biomed Stock (NASDAQ: MYNZ) and witnessed a commendable (+31.15%) growth – it’s time to pop the corks and let the champagne flow! 🥂
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
Your trust in our Equity Trader Ai, the foresight of Cantor Fitzgerald, and the relentless team at MYNZ is paying off. We’ve always believed that our community deserves more than just a beer, and today, that champagne toast is well-deserved.
As of September 13th, 2023, recent data reveals that Mainz Biomed (NASDAQ: MYNZ) ColoAlert Next Generation(1) boasts an impressive 81% Sensitivity for Advanced Adenoma, significantly outpacing Exact Sciences Corp (NASDAQ: EXAS) at 43%.”
This is significant for several reasons:
Higher Detection Rate: An 81% sensitivity means that Mainz Biomed’s (NASDAQ: MYNZ) test can correctly identify 81 out of 100 patients with Advanced Adenoma. In contrast, the (NASDAQ: EXAS) Cologuard test would only correctly identify 43 out of 100 patients with the same condition. This higher detection rate can lead to earlier and more accurate diagnoses.
Patient Safety and Care: Advanced Adenomas are precancerous lesions. Detecting them early and accurately is crucial for timely intervention, which can prevent the progression to colorectal cancer. A test with higher sensitivity can save lives by catching the disease in its early, more treatable stages.
The recent report on Mainz Biomed Stock (NASDAQ: MYNZ) ( +31.15%) past days. ColoAlert Next Generation(1) is awe-inspiring. It not only reinforces our collective belief in the stock but also sends a clear message to the industry behemoths. “Yes, we’re looking at you…Exact Sciences Corp NASDAQ: EXAS. (-4.74%) past 5 days ”, which saw a dip of -4.74% over the past 5 days.” The tables are turning as MYNZ continues to outperform and challenge the dominance of industry giants like EXAS.
In the world of colorectal cancer diagnostics, it feels like the biblical tale of David and Goliath is unfolding. David (Mainz Biomed) is gearing up to challenge Goliath (Exact Sciences), especially with MYNZ’s focus on creating one of the most affordable solutions in the market.
Let’s dive into the details:
Mainz Biomed vs. Exact Sciences Corp: The Showdown in Colorectal Cancer Diagnostics
|Metric/Method||Mainz Biomed Stock (NASDAQ: MYNZ) ColoAlert Next Generation(1)||Exact Sciences Corp (NASDAQ: EXAS) Cologuard Next Generation(2)|
|Sensitivity for Colorectal Cancer||94%||94%|
|Specificity for Colorectal Cancer||97%||91%|
|Sensitivity for Advanced Adenoma||81%||43%|
|Ease of Use||Easy-to-use||Easy-to-use|
|Market Reach||Poised for a significant market presence with its impending FDA pivotal study in 2024||FDA cleared and already marketed in the U.S.|
- As reported by the Mainz Biomed on September 13, 2023
- As reported by Exact Sciences on June 20, 2023
Financial Forecast & Market Capitalization:
The past week has seen MYNZ’s stock price surge by +10.91%. This bullish trajectory suggests that the market’s anticipation and confidence in MYNZ are soaring. With Cantor Fitzgerald’s bullish sentiment, there’s a projection of MYNZ’s growth to a $9 price target, indicating a potential increase of about +145.9%.
When we compare the market capitalization of MYNZ, which stands at $57.21M, with that of EXAS’s hefty market cap of $14.20B, the disparity in valuation showcases a significant upside potential for MYNZ investors. This vast difference in market cap, combined with MYNZ’s recent performance and promising prospects, suggests that there’s a substantial room for growth for MYNZ.
For a moment of reflection, let’s remember that tech giants like Apple and Amazon also began their journeys with stocks in the $3 territory. Their stories are a testament to the potential of companies with the right strategy, innovation, and market positioning. For MYNZ investors, this could mean unparalleled growth, especially if MYNZ continues its current trajectory.
Economic Implications: Misdiagnoses or late diagnoses can lead to more invasive treatments, longer hospital stays, and increased medical costs. A more sensitive test can reduce these costs by enabling earlier, less invasive interventions.
Investor Confidence: For stakeholders and investors, the efficacy of a company’s product can influence investment decisions. A product that outperforms competitors can lead to increased investor confidence and potentially higher stock prices.
Reputation and Trust: In the medical field, the accuracy and reliability of tests are paramount. A test with high sensitivity can bolster the reputation of the company, leading to increased trust among patients, doctors, and other healthcare professionals.
- ColoFuture Study Results: Mainz Biomed’s recent ColoFuture study has reported groundbreaking topline results. The study demonstrated a sensitivity for colorectal cancer of 94% with a specificity of 97%. Additionally, it showed an advanced adenoma sensitivity of 81%.
- Potential FDA PMA Clinical Trial Integration: The company has identified multiple novel mRNA biomarkers for potential integration into the pivotal FDA PMA clinical trial (ReconAAsense).
- ColoAlert®: Mainz Biomed’s flagship product, ColoAlert®, is a non-invasive test that offers better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert® detects more cases of colorectal cancer than other stool tests.
- Market Opportunity: With roughly one-third of US residents aged 50-75 having never been screened for colon cancer, this represents a $4.0B+ total market opportunity in the US.
In summary, the significant difference in sensitivity between Mainz Biomed’s and Exact Sciences Corp’s tests can have profound implications for patient care, the economic landscape of medical treatments, and the business trajectories of both companies.
Disclaimer: This newsletter is for informational purposes only and should not be considered financial advice. Always conduct your own research before making any investment decisions.